皮肤毒性测试市场 - 全球产业规模、份额、趋势、机会和预测，按测试类型、按测试方法类型（体内测试和体外测试）、按最终用户、按地区和竞争细分，2020 年至 2030 年

2024 年全球皮肤毒性​​测试市场价值为 21 亿美元，预计在预测期内将实现令人印象深刻的成长，到 2030 年的复合年增长率为 8.15%。全球皮肤毒性​​测试市场正在稳步增长，这得益于监管要求、对动物试验的伦理担忧、技术进步以及研发 (R&D) 投资的增加。该市场对于製药、化妆品、化学和生物技术行业至关重要，确保产品进入市场前的安全和法规合规性。

FDA（美国）、EMA（欧洲）和OECD等监管机构已经制定了严格的皮肤毒性评估安全协议，迫使公司采用先进的测试方法。受监管变化、尖端创新以及消费者对安全、道德和无残忍产品日益增长的需求的推动，该行业正在经历重大转型。

儘管初始成本高和监管标准化等挑战依然存在，但持续的研发努力、新兴经济体不断扩大的市场机会以及策略性产业合作正在开闢新的成长途径。随着非动物测试方法的日益普及，市场有望继续扩张，并加强其在塑造全球范围内药品、化妆品和化学品安全测试未来方面的关键作用。

关键市场驱动因素

禁止动物试验的现像日益增多，替代方法的兴起

主要市场挑战

替代方法的验证

主要市场趋势

先进的体外模型

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球皮肤毒性​​测试市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依测试类型（皮肤刺激测试、皮肤致敏测试）
  • 依测试方法类型（体内测试（基于动物的测试）、体外测试（基于细胞或基于组织的测试））
  • 按最终用户（製药业、化妆品和个人护理产品行业、化学工业、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美皮肤毒性测试市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲皮肤毒性测试市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太皮肤毒性测试市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美皮肤毒性测试市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲皮肤毒性测试市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：全球皮肤毒性​​测试市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章：竞争格局

• SGS SA
• Covance, Inc
• Bio-Rad Laboratories Inc.
• Qiagen NV
• GE Healthcare
• Eurofins Scientific Inc
• Merck KgaA
• Thermo Fisher Scientific, Inc.
• Charles River Laboratories International, Inc.
• Catalent, Inc

第 16 章：策略建议

第17章调查会社について・免责事项

Global Dermal Toxicity Testing Market was valued at USD 2.10 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.15% through 2030. The Global Dermal Toxicity Testing Market is witnessing steady growth, driven by regulatory mandates, ethical concerns over animal testing, technological advancements, and increased investments in research and development (R&D). This market is essential to the pharmaceutical, cosmetic, chemical, and biotechnology industries, ensuring product safety and regulatory compliance before market entry.

Regulatory bodies such as the FDA (U.S.), EMA (Europe), and OECD have established stringent safety protocols for dermal toxicity assessment, compelling companies to adopt advanced testing methodologies. The industry is undergoing a significant transformation, fueled by regulatory changes, cutting-edge innovations, and growing consumer demand for safe, ethical, and cruelty-free products.

While challenges such as high initial costs and regulatory standardization remain, ongoing R&D efforts, expanding market opportunities in emerging economies, and strategic industry collaborations are unlocking new avenues for growth. With the increasing adoption of non-animal testing methods, the market is poised for continued expansion, reinforcing its critical role in shaping the future of safety testing across pharmaceuticals, cosmetics, and chemicals on a global scale.

Key Market Drivers

Growing Ban on Animal Testing and Shift Toward Alternative Methods

The increasing global restrictions on animal testing have become a significant catalyst for the growth of the Global Dermal Toxicity Testing Market. As ethical concerns, regulatory pressures, and technological advancements converge, industries are rapidly transitioning toward alternative testing methods that are more reliable, cost-effective, and aligned with modern scientific standards. Over the past two decades, several governments and regulatory bodies have implemented strict prohibitions on animal testing, particularly in the cosmetics, pharmaceuticals, and chemical industries. The Cosmetics Regulation (EC) No 1223/2009 introduced: A testing ban: Animal testing on finished cosmetic products has been banned since September 2004, and testing on ingredients has been banned since March 2009. These nations have followed suit with similar bans on animal-tested cosmetics. While the FDA does not outright ban animal testing, states like California, Illinois, and New Jersey have imposed restrictions, leading to increased adoption of alternative testing approaches. Historically a proponent of animal testing, China has relaxed its regulations, now allowing non-animal methods for certain imported and domestically manufactured cosmetics. As regulatory compliance becomes non-negotiable, companies worldwide are investing heavily in alternative toxicity testing solutions, thus fueling market growth.

Key Market Challenges

Validation of Alternative Methods

The validation of alternative methods can pose challenges and potentially hinder the growth of the global dermal toxicity testing market. While alternative methods are sought after due to their ethical considerations and scientific advancements, their validation process can be complex and time-consuming. The validation of alternative methods requires extensive research, data collection, and comparison to established reference methods, often including animal testing benchmarks. This process can be time-consuming and resource-intensive, slowing down the adoption of these methods. As a result, market growth might be hindered, especially in the short term. Regulatory bodies typically require validation data to demonstrate the reliability and predictability of alternative methods. The acceptance of these methods in regulatory frameworks may take time, as agencies need to be convinced of their equivalence to existing methods. This delay can slow down the market growth, as companies hesitate to fully adopt alternative methods until they receive regulatory approval. The validation process aims to establish consistent and reproducible results across different laboratories and testing conditions. Variability in results can arise due to differences in protocols, equipment, or expertise. This lack of consistency can lead to skepticism about the reliability of alternative methods, causing some companies to hesitate in adopting them until these issues are resolved.

Key Market Trends

Advanced In Vitro Models

Advanced in vitro models better replicate human skin physiology, allowing for more accurate predictions of dermal toxicity. These models can mimic skin barrier function, cellular interactions, and complex biological processes, providing more reliable insights into how substances interact with human skin. As accuracy improves, industries can confidently assess potential hazards and make informed decisions about product safety. The use of animals for testing raises ethical concerns, and industries are increasingly turning to non-animal methods. Advanced in vitro models offer an ethical alternative by eliminating the need for animal testing while still providing scientifically meaningful results. Brands that prioritize ethical testing practices can enhance their reputation and appeal to consumers who value cruelty-free products. Regulatory bodies are recognizing the value of advanced in vitro models for safety assessment. As these methods become more validated and established, regulatory acceptance is increasing. Industries can use these methods to fulfill regulatory requirements, which accelerates their adoption and drives market growth. In vitro models offer quicker results compared to animal testing, allowing industries to streamline their testing processes and reduce time-to-market. Additionally, the ability to test multiple substances simultaneously enhances efficiency. While initial setup costs might be involved, the long-term cost-effectiveness of in vitro models can drive their adoption and market growth. Advanced in vitro models can be customized to mimic specific skin types, conditions, and populations. This flexibility enables industries to tailor testing to their products' target audiences, improving the relevance and accuracy of toxicity assessments. This customization can attract industries seeking personalized and precise testing solutions.

Key Market Players

• SGS S.A.
• Covance, Inc
• Bio-Rad Laboratories Inc.
• Qiagen N.V.
• GE Healthcare
• Eurofins Scientific Inc
• Merck KgaA
• Thermo Fisher Scientific, Inc.
• Charles River Laboratories International, Inc.
• Catalent, Inc.

Report Scope:

In this report, the Global Dermal Toxicity Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermal Toxicity Testing Market, By Test Type:

• Skin Irritation Tests
• Skin Sensitization Tests

Dermal Toxicity Testing Market, By Testing Method Type:

• In Vivo Testing (Animal-Based Tests)
• In Vitro Testing (Cell-Based or Tissue-Based Tests)

Dermal Toxicity Testing Market, By End User:

• Pharmaceuticals industries
• Cosmetics and personal care products industry
• Chemical Industry
• Other

Dermal Toxicity Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dermal Toxicity Testing Market.

Available Customizations:

Global Dermal Toxicity Testing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dermal Toxicity Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Skin Irritation Tests, Skin Sensitization Tests)
  • 5.2.2. By Testing Method Type (In Vivo Testing (Animal-Based Tests), In Vitro Testing (Cell-Based or Tissue-Based Tests))
  • 5.2.3. By End User (Pharmaceuticals industries, Cosmetics and personal care products industry, Chemical Industry, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Dermal Toxicity Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Testing Method Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dermal Toxicity Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Testing Method Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Dermal Toxicity Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Testing Method Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Dermal Toxicity Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Testing Method Type
      • 6.3.3.2.3. By End User

7. Europe Dermal Toxicity Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Testing Method Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Dermal Toxicity Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Testing Method Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Dermal Toxicity Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Testing Method Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Dermal Toxicity Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Testing Method Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Dermal Toxicity Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Testing Method Type
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Dermal Toxicity Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Testing Method Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Dermal Toxicity Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Testing Method Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Dermal Toxicity Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Testing Method Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Dermal Toxicity Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Testing Method Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Dermal Toxicity Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Testing Method Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Dermal Toxicity Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Testing Method Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Dermal Toxicity Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Testing Method Type
      • 8.3.5.2.3. By End User

9. South America Dermal Toxicity Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Testing Method Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Dermal Toxicity Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Testing Method Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Dermal Toxicity Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Testing Method Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Dermal Toxicity Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Testing Method Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Dermal Toxicity Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Testing Method Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Dermal Toxicity Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Testing Method Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Dermal Toxicity Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Testing Method Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Dermal Toxicity Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Testing Method Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Dermal Toxicity Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. SGS S.A.
  • 15.1.1. Business Overview
  • 15.1.2. Product & Service Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (If Listed)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. Covance, Inc
• 15.3. Bio-Rad Laboratories Inc.
• 15.4. Qiagen N.V.
• 15.5. GE Healthcare
• 15.6. Eurofins Scientific Inc
• 15.7. Merck KgaA
• 15.8. Thermo Fisher Scientific, Inc.
• 15.9. Charles River Laboratories International, Inc.
• 15.10. Catalent, Inc

16. Strategic Recommendations

17. About Us & Disclaimer